Editorial: the role for PIVKA-II measurement after HCV elimination by direct-acting antivirals in terms of prediction of hepatocellular carcinoma-authors' reply

Aliment Pharmacol Ther. 2022 Jan;55(1):124-125. doi: 10.1111/apt.16710.

Authors

Elisabetta Degasperi¹, Roberta D'Ambrosio¹, Pietro Lampertico^{1

2}

Affiliations

¹ Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Milan, Italy.

PMID: 34907557
DOI: 10.1111/apt.16710

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antiviral Agents / therapeutic use
Biomarkers
Carcinoma, Hepatocellular* / drug therapy
Hepatitis C, Chronic* / drug therapy
Humans
Liver Neoplasms* / drug therapy
Protein Precursors
Prothrombin

Substances

Antiviral Agents
Biomarkers
Protein Precursors
acarboxyprothrombin
Prothrombin